|1.||Guo, Wei: 3 articles (04/2011 - 09/2008)|
|2.||Fang, Bingliang: 3 articles (04/2011 - 09/2008)|
|3.||Wu, Shuhong: 3 articles (04/2011 - 09/2008)|
|4.||Wei, Xiaoli: 2 articles (04/2011 - 01/2011)|
|5.||Wang, Li: 2 articles (04/2011 - 01/2011)|
|6.||Liu, Jinsong: 2 articles (04/2011 - 09/2008)|
|7.||Liu, Xiaoying: 2 articles (04/2011 - 01/2011)|
|8.||Wang, Ji: 1 article (01/2011)|
|9.||Lu, Zhimin: 1 article (01/2011)|
|10.||Hollingshead, Melinda: 1 article (01/2011)|
04/28/2011 - "About 40 of those compounds were as potent as or more potent than oncrasin-1 in tumor cells and had a minimal cytotoxic effect on normal cells. "
01/01/2011 - "To optimize the antitumor activity of oncrasin-1, a small molecule identified through synthetic lethality screening on isogenic K-Ras mutant tumor cells, we developed several analogues and determined their antitumor activities. "
09/15/2008 - "Our results indicate that oncrasin-1 or its active analogues could be a novel class of anticancer agents, which effectively kill K-Ras mutant cancer cells."
09/15/2008 - "The in vivo administration of oncrasin-1 suppressed the growth of K-ras mutant human lung tumor xenografts by >70% and prolonged the survival of nude mice bearing these tumors, without causing detectable toxicity. "
04/28/2011 - "To optimize the antitumor activity of oncrasin-1, a small molecule RNA polymerase II inhibitor, we evaluated 69 oncrasin-1 analogues for their cytotoxic activity against normal human epithelial cells and K-Ras mutant tumor cells. "
|1.||RNA Polymerase II (RNA Polymerase B)
|1.||Heterologous Transplantation (Xenotransplantation)